DMD Gene Therapy Evolution: From Exon Skipping to Precision Humanized Models
On January 26, 2026, Sarepta Therapeutics announced positive three-year data from the Phase 3 clinical trial of its DMD gene therapy, Elevidys. The results demonstrated a 70% reduction in the rate of functional decline among treated patients, with no new treatment-related safety signals observed. This announcement brought a wave of much-needed optimism to the recently turbulent landscape of DMD gene therapy. Looking back at the decades-long journey of DMD drug development, the path has been fraught with challenges and breakthroughs. Every step forward embodies the dedication of researchers, pharmaceutical companies, and the patient community, with Sarepta's trajectory serving as a microcosm of this profound history.
1. DMD Pathology & Traditional Steroids: The Foundation of Care (Late 20th Century - 2015)
Duchenne Muscular Dystrophy (DMD) is a severe X-linked neuromuscular genetic disorder. Its core pathology stems from mutations in the DMD gene, leading to a complete absence of dystrophin. This results in progressive degeneration of skeletal and cardiac muscle, and an irreversible loss of muscle function. Primarily affecting males, the global incidence of DMD is approximately 1 in 3,500 to 5,000 live male births, with a worldwide patient population exceeding 300,000 and over 20,000 new cases diagnosed annually.
In the early stages of drug development, medical understanding of DMD was limited, and therapeutic options were scarce. Treatments primarily focused on symptom management, making corticosteroid drugs the reluctant but only choice.
Figure 2. DMD Disease Progression [1].
While the classic drug Deflazacort (Emflaza®) effectively delays the progression of muscle weakness and maintains muscle strength, it carries significant side effects, including stunted growth and osteoporosis. Furthermore, Ataluren (Translarna™), a protein restoration therapy targeting nonsense mutations, had its marketing authorization non-renewed by the European Medicines Agency due to controversial clinical trial results. Its resubmitted New Drug Application (NDA) is currently under FDA review, with a decision expected in early 2026 [2]. Consequently, the continuous research and advancement of novel therapies remains an urgent necessity.
2. Vamorolone: The Rise of Dissociative Steroids in DMD Therapy (2023 - Present)
Recently, Vamorolone (Agamree®), the first approved dissociative steroid, achieved a crucial balance between efficacy and safety. It provides equivalent muscle protection while circumventing the severe side effects associated with traditional corticosteroids, and has been approved and rolled out globally across the US, Europe, and China.
Figure 3. Mechanism of Action Comparison: Prednisolone vs. Vamorolone [3].
3. Exon Skipping Revolution: First-Generation ASO Therapies for DMD (2016 - 2020)
Advancements in molecular biology ushered in the first major turning point in DMD drug development: Antisense Oligonucleotide (ASO) therapies. Sarepta pioneered this space; in 2016, its drug EXONDYS 51 (Eteplirsen) received accelerated FDA approval for patients amenable to exon 51 skipping. As the world's first ASO drug for DMD, it marked the dawn of the targeted therapy era.
ASO therapies function by targeting the gene transcription process, guiding cells to "skip" mutated exons, thereby restoring partial expression of dystrophin. Capitalizing on this mechanism, Sarepta subsequently launched VYONDYS 53 (Golodirsen) in 2019 and AMONDYS 45 (Casimersen) in 2021, broadening the scope of treatable patients.
However, early ASO therapies were not without flaws. They required lifelong weekly intravenous administration, resulting in high costs and poor patient compliance. More critically, the clinical efficacy of certain ASO drugs sparked debate; for instance, Sarepta's Amondys 45 and Vyondys 53 failed to significantly improve motor function in Phase 3 clinical trials [4].
4. Next-Generation ASOs: Targeted Muscle Delivery and Exon 53 Skipping (2020 - Present)
Next-generation ASO therapies represent a qualitative leap in technology. Wave Life Sciences is advancing an ASO for a specific subpopulation amenable to exon 53 skipping, with an NDA submission on track for 2026 [5].
Meanwhile, Dyne Therapeutics' z-rostudirsen and Avidity Biosciences' del-zota have utilized TfR1-targeted monoclonal antibodies to achieve precise drug delivery to muscle cells, increasing protein expression levels tenfold compared to first-generation therapies [6-7]. Del-zota targets exon 44 skipping, while z-rostudirsen targets exon 51. In November 2025, an FDA-authorized "Managed Access Program" was initiated for del-zota, allowing eligible patients early access prior to formal approval. Numerous global biopharma companies are accelerating pipeline developments covering exons 44, 45, 50, 51, 52, and 53, with several having completed efficacy validation in mouse and cynomolgus monkey models.
Figure 4. Structure and Mechanism of Avidity Biosciences' del-zota [8].
5. DMD Gene Therapy: Navigating the Safety & Efficacy of Elevidys (2020 - 2025)
As ASOs progressed steadily, gene therapy rapidly became the "new darling" of DMD drug development, driven by its potential as a "one-time cure". Sarepta once again took the spotlight. On June 22, 2023, Sarepta's Elevidys (SRP-9001) received FDA approval as the world's first one-time gene therapy for DMD, indicated for ambulatory children aged 4-5. This milestone electrified the field.
Elevidys packages a mini-dystrophin transgene within an AAV vector. A single intravenous infusion enables the patient's muscles to produce a partially functional recombinant protein. Theoretically effective for patients with various DMD gene mutations, it solved the challenge of the DMD gene being too large for conventional viral vectors.
However, clinical translation faced severe turbulence. In 2025, two non-ambulatory patients died from acute liver failure following Elevidys treatment, prompting the FDA to restrict its use to ambulatory patients over 4 years old and issue a black box warning [9]. Similarly, in May 2024, Pfizer announced the death of a patient from cardiac arrest in the Phase 2 trial of its gene therapy, fordadistrogene movaparvovec—following a previous death in a 2021 Phase 1b study. These safety events triggered a re-evaluation of gene therapy's risk-reward profile.
6. Sarepta's 2026 Data: Mitigating Gene Therapy Risks with Rapamycin (2025 - Present)
Addressing these clinical hurdles, Sarepta developed an enhanced immunosuppression protocol utilizing rapamycin, effectively mitigating the risk of post-treatment liver injury. The positive three-year Phase 3 data released in January 2026 [10] reaffirms the therapy's safety and functional benefits. Currently, multiple companies are advancing next-generation gene therapies, primarily in Phase 2 or earlier clinical stages.
7. Emerging Pipelines: Cell Therapy and Cardiac Function in DMD (2024 - Present)
Beyond ASOs and gene therapies, other innovative modalities are filling clinical gaps. Capricor Therapeutics developed Deramiocel, a cell therapy targeting DMD-associated cardiomyopathy—the leading cause of mortality in DMD patients. Late 2025 Phase 3 data showed the therapy delayed upper limb functional decline by 54% and cardiac functional decline by 91% [11]. A Biologics License Application (BLA) submission is expected in 2026.
8. Preclinical Validation: Humanized DMD Mouse Models for Drug R&D
The fundamental difficulty in DMD research lies in its complex pathology: the DMD gene is one of the largest in the human genome, with diverse and scattered mutation types, compounding the challenge of targeted intervention. Furthermore, the physiological barrier of muscle tissue complicates drug delivery. Consequently, precise mouse models that mimic human DMD pathology are indispensable for uncovering disease mechanisms, validating therapeutic targets, and screening drug candidates.
Classic Murine Model: mdx Mice — The mdx mouse is the most classic DMD model, characterized by a spontaneous nonsense mutation (Q995X) in the Dmd gene, leading to truncated, non-functional protein and absent dystrophin. While highly valuable for early drug screening, its limitation is a slower disease progression compared to human DMD.
Humanized Models: The "Experimental Surrogates" — Humanized mouse models express the human dystrophin gene, demonstrating high consistency with human pathology and drug response. They are the current "gold standard" for preclinical validation of novel DMD therapies. For example, the hDMDdel52/mdx model has been widely utilized by leading companies like BioMarin and Sarepta for ASO preclinical testing, directly accelerating clinical IND applications [12-13].
At Cyagen, we prioritize scientific excellence by offering a comprehensive suite of DMD models. Beyond various mdx models, we have developed multiple humanized DMD models covering different exon regions. To support the next generation of targeted therapies, we also provide models co-expressing muscle-targeted delivery receptors, such as TfR1.
| Product Code | Product Name | Background Strain |
|---|---|---|
| C001518 | DMD-Q995* | C57BL/6 |
| C001773 | DMD-Q995*(DBA2;B6) | DBA2;B6 |
| I001224 | hDMD(E8-30) | C57BL/6 |
| C001775 | hDMD(E49-53) | C57BL/6 |
| C001881 | hDMD(E49-53)-Del(E50) | C57BL/6 |
| C001595 | hTFRC/hDMD(E49-53) | C57BL/6 |
| C001596 | hTFRC/hDMD(E8-30) | C57BL/6 |
9. Future Outlook: Advancing Toward Precision DMD Gene Cures
Today, DMD treatment still faces significant challenges, including the safety monitoring of novel therapies, drug accessibility, and a lack of treatments for certain rare mutation types. Yet, the trajectory of companies like Sarepta—from EXONDYS 51 to Elevidys—reflects the relentless perseverance of the entire scientific community. Driven by deeper foundational research, advanced drug delivery technologies, and global collaboration, the field is steadily marching toward "precision cures." This progress not only restores hope to patients but also marks a critical step forward in humanity's ability to rewrite our genetic destinies.
10. References
[1] Łoboda A, Dulak J. Cell therapy for Duchenne muscular dystrophy: promises, challenges, and controversies. Cell Mol Life Sci. 2025 Oct 11;82(1):356.
[2] European Medicines Agency. Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine [Internet]. Amsterdam (NL): EMA; 2024 Oct 18 [cited 2026 Jan 29]. Available from: https://www.ema.europa.eu/en/news/translarna-ema-re-confirms-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine
[3] D'Ambrosio ES, Mendell JR. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy. Neurotherapeutics. 2023 Oct;20(6):1669-1681.
[4] Sarepta Therapeutics, Inc. Sarepta Therapeutics announces third quarter 2025 financial results and recent corporate developments [Internet]. Cambridge (MA): Sarepta Therapeutics, Inc.; 2025 Nov 3. Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2025-financial
[5] Wave Life Sciences Ltd. Wave Life Sciences announces positive data from FORWARD-53 clinical trial in DMD [Internet]. Cambridge (MA): Wave Life Sciences Ltd.; 2025 Mar 26. Available from: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-data-forward-53-clinical
[6] Dyne Therapeutics, Inc. Pipeline [Internet]. Waltham (MA): Dyne Therapeutics, Inc.; 2026. Available from: https://www.dyne-tx.com/pipeline/
[7] Avidity Biosciences, Inc. Avidity Biosciences announces U.S. Managed Access Program (MAP) for investigational therapy del-zota in DMD44 [Internet]. San Diego (CA): Avidity Biosciences, Inc.; 2025 Nov 19. Available from: https://investors.aviditybiosciences.com/2025-11-19-Avidity-Biosciences-Announces-U-S-Managed-Access-Program-MAP-for-Investigational-Therapy-del-zota-in-DMD44
[8] Stahl M, Zhu Y, Goel V, et al. AOC 1044 as a novel therapeutic approach for DMD patients amenable to exon 44 skipping: EXPLORE44 phase 1/2 healthy volunteer data. Poster presented at: 2024 MDA Clinical & Scientific Conference; 2024 Mar 3-6; Orlando, FL. Available from: https://www.aviditybiosciences.com/sites/default/files/2025-04/MDA-2024-EXPLORE44-HV-Poster_6.0_STC.pdf
[9] U.S. Food and Drug Administration. FDA approves new safety warning and revised indication that limits use for Elevidys following reports of fatal liver injury [Internet]. Silver Spring (MD): FDA; 2025 Nov 14. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal
[10] Sarepta Therapeutics, Inc. Sarepta announces positive topline three-year EMBARK results showing ELEVIDYS significantly slows disease progression [Internet]. Cambridge (MA): Sarepta Therapeutics, Inc.; 2026 Jan 26. Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results
[11] Capricor Therapeutics, Inc. Capricor Therapeutics provides regulatory update on deramiocel BLA following FDA review of HOPE-3 topline data [Internet]. San Diego (CA): Capricor Therapeutics, Inc.; 2026 Jan 20. Available from: https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on
[12] Oppeneer T, Qi Y, Henshaw J, et al. Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Induces Enhanced Exon Skipping in a Mouse Model of Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2025;35(2):68-80.
[13] Braunreiter K, Kempton A, Mejia-Guerra MK, et al. Characterization of a humanized mouse model of Duchenne muscular dystrophy to support the development of genetic medicines. Dis Model Mech. 2025 Oct 1;18(10):dmm052182.
